A Comparison of Ku0063794, a Dual mTORC1 and mTORC2 Inhibitor, and Temsirolimus in Preclinical Renal Cell Carcinoma Models
Figure 2
Intracellular signaling in RCC cells treated with Ku0063794 or temsirolimus.
Caki-1 (A) and 786-O (B) cells were treated with Ku0063794 at the indicated concentrations for the indicated length of time. Control cells treated with DMSO were treated for 3 hrs. Cell lysates were used for western blotting to analyze the mTORC1/2 pathway. In an analogous experiment, Caki-1 (C) and 786-O (D) cells were similarly treated with temsirolimus or DMSO. The figure is representative of triplicate experiments.